Depression and anxiety before and at the beginning of the COVID-19 pandemic and incident persistent symptoms: a prospective population-based cohort study.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
19 Jul 2023
19 Jul 2023
Historique:
received:
09
02
2023
accepted:
03
07
2023
revised:
09
06
2023
medline:
19
7
2023
pubmed:
19
7
2023
entrez:
18
7
2023
Statut:
aheadofprint
Résumé
Many patients affected by COVID-19 suffer from debilitating persistent symptoms whose risk factors remained poorly understood. This prospective study examined the association of depression and anxiety symptoms measured before and at the beginning of the COVID-19 pandemic with the incidence of persistent symptoms. Among 25,114 participants [mean (SD) age, 48.72 years (12.82); 51.1% women] from the SAPRIS and SAPRIS-Sérologie surveys nested in the French CONSTANCES population-based cohort, depression and anxiety symptoms were measured with the Center for Epidemiologic Studies-Depression scale and the 12-item General Health Questionnaire before the pandemic, and with the 9-item Patient Health Questionnaire and the 7-Item Generalized Anxiety Disorder scale at the beginning of the pandemic (i.e., between April 6, 2020 and May 4, 2020). Incident persistent symptoms were self-reported between December 2020 and January 2021. The following variables were also considered: gender, age, educational level, household income, smoking status, BMI, hypertension, diabetes, self-rated health, and SARS-CoV-2 infection according to serology/PCR test results. After a follow-up of seven to ten months, 2329 participants (9.3%) had been infected with SARS-CoV-2 and 4262 (17.0%) reported at least one incident persistent symptom that emerged from March 2020, regardless of SARS-CoV-2 infection. In multi-adjusted logistic regression models, participants in the highest (versus the lowest) quartile of depressive or anxiety symptom levels before or at the beginning of the pandemic were more likely to have at least one incident persistent symptom (versus none) at follow-up [OR (95%CI) ranging from 2.10 (1.89-2.32) to 3.01 (2.68-3.37)], with dose-response relationships (p for linear trend <0.001). Overall, these associations were significantly stronger in non-infected versus infected participants, except for depressive symptoms at the beginning of the pandemic. Depressive symptoms at the beginning of the pandemic were the strongest predictor of incident persistent symptoms in both infected and non-infected participants [OR (95%CI): 2.88 (2.01-4.14) and 3.03 (2.69-3.42), respectively]. In exploratory analyses, similar associations were found for each symptom taken separately in different models. Depression and anxiety symptoms should be tested as a potential target for preventive interventions against persistent symptoms after an infection with SARS-CoV-2.
Identifiants
pubmed: 37464077
doi: 10.1038/s41380-023-02179-9
pii: 10.1038/s41380-023-02179-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agence Nationale de la Recherche (French National Research Agency)
ID : ANR-10-COHO-06
Organisme : Agence Nationale de la Recherche (French National Research Agency)
ID : ANR-20-COVI-000
Organisme : Agence Nationale de la Recherche (French National Research Agency)
ID : ANR-11-INBS-0002
Organisme : Agence Nationale de la Recherche (French National Research Agency)
ID : ANR-10-COHO-06
Organisme : Agence Nationale de la Recherche (French National Research Agency)
ID : ANR-20-COVI-000
Organisme : Agence Nationale de Recherches sur le Sida et les Hépatites Virales (National Agency for AIDS Research)
ID : AAP Covid long 2022-1
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Robineau O, Zins M, Touvier M, Wiernik E, Lemogne C, de Lamballerie X, et al. Long-lasting symptoms after an acute covid-19 infection and factors associated with their resolution. JAMA Netw Open. 2022;5(nov):e2240985.
pubmed: 36350653
pmcid: 9647489
doi: 10.1001/jamanetworkopen.2022.40985
Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM. Lifelines corona research initiative. persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400(août):452–61.
pubmed: 35934007
pmcid: 9352274
doi: 10.1016/S0140-6736(22)01214-4
Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. WHO clinical case definition working group on post-COVID-19 condition. a clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(avr):e102–7.
pubmed: 34951953
doi: 10.1016/S1473-3099(21)00703-9
Fleischer M, Szepanowski F, Tovar M, Herchert K, Dinse H, Schweda A, et al. Post-COVID-19 Syndrome is Rarely Associated with Damage of the Nervous System: Findings from a Prospective Observational Cohort Study in 171 Patients. Neurol Ther. 2022;11:1637–57.
Kachaner A, Lemogne C, Dave J, Ranque B, de Broucker T, Meppiel E. Somatic symptom disorder in patients with post-COVID-19 neurological symptoms: a preliminary report from the somatic study (Somatic Symptom Disorder Triggered by COVID-19). J Neurol Neurosurg Psychiatry. 2022:jnnp-2021-327899. https://doi.org/10.1136/jnnp-2021-327899 . Epub ahead of print.
Scherlinger M, Felten R, Gallais F, Nazon C, Chatelus E, Pijnenburg L, et al. Refining « long-COVID » by a prospective multimodal evaluation of patients with long-term symptoms attributed to SARS-CoV-2 Infection. Infect Dis Ther. 2021;10(sept):1747–63.
pubmed: 34245450
pmcid: 8270770
doi: 10.1007/s40121-021-00484-w
Ladlow P, O’Sullivan O, Houston A, Barker-Davies R, May S, Mills D, et al. Dysautonomia following COVID-19 is not associated with subjective limitations or symptoms but is associated with objective functional limitations. Heart Rhythm. 2022;19:613–20.
pubmed: 34896622
doi: 10.1016/j.hrthm.2021.12.005
Petersen EL, Goßling A, Adam G, Aepfelbacher M, Behrendt CA, Cavus E, et al. Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: the Hamburg city health study COVID programme. Eur Heart J. 2022;43(mars):1124–37.
pubmed: 34999762
pmcid: 8755397
doi: 10.1093/eurheartj/ehab914
Sneller MC, Liang CJ, Marques AR, Chung JY, Shanbhag SM, Fontana JR, et al. A longitudinal study of COVID-19 sequelae and immunity: baseline findings. Ann Intern Med. 2022;175(juill):969–79.
pubmed: 35605238
doi: 10.7326/M21-4905
Selvakumar J, Havdal LB, Drevvatne M, Brodwall EM, Lund Berven L, Stiansen-Sonerud T, et al. Prevalence and characteristics associated with post–COVID-19 condition among nonhospitalized adolescents and young adults. JAMA Network Open. 2023;6(mars):e235763.
pubmed: 36995712
pmcid: 10064252
doi: 10.1001/jamanetworkopen.2023.5763
Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604(avr):697–707.
pubmed: 35255491
pmcid: 9046077
doi: 10.1038/s41586-022-04569-5
Heiss R, Tan L, Schmidt S, Regensburger AP, Ewert F, Mammadova D, et al. Pulmonary Dysfunction after Pediatric COVID-19. Radiology. 2023;306:e221250.
Gaffney AW. The long COVID conundrum. Am J Med. 2022;135(janv):5–6.
pubmed: 34428463
doi: 10.1016/j.amjmed.2021.07.037
Scherlinger M, Lemogne C, Felten R, Sibilia J. Excess of post-acute sequelae of COVID-19 after the first wave of the pandemic. Infect Dis Ther. 2022;11:2279–85.
Lemogne C, Gouraud C, Pitron V, Ranque B. Why the hypothesis of psychological mechanisms in long COVID is worth considering. J Psychosom Res. 2023;165(févr):111135.
pubmed: 36623391
pmcid: 9825049
doi: 10.1016/j.jpsychores.2022.111135
Matta J, Wiernik E, Robineau O, Severi G, Touvier M, Gouraud C, et al. Trust in sources of information on COVID-19 at the beginning of the pandemic’s first wave and incident persistent symptoms in the population-based CONSTANCES cohort: a prospective study. J Psychosom Res. 2023;169:111326.
Wang S, Quan L, Chavarro JE, Slopen N, Kubzansky LD, Koenen KC, et al. Associations of depression, anxiety, worry, perceived stress, and loneliness prior to infection with risk of post-COVID-19 conditions. JAMA Psychiatry. 2022;79(nov):1081–91.
pubmed: 36069885
pmcid: 9453634
doi: 10.1001/jamapsychiatry.2022.2640
Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(juill):993–8.
pubmed: 32730238
pmcid: 7392393
doi: 10.15585/mmwr.mm6930e1
Hirschtick JL, Titus AR, Slocum E, Power LE, Hirschtick RE, Elliott MR, et al. Population-based estimates of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) prevalence and characteristics. Clin Infect Dis. 2021;73(déc):2055–64.
pubmed: 34007978
doi: 10.1093/cid/ciab408
Matta J, Wiernik E, Robineau O, Carrat F, Touvier M, Severi G, et al. Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among french adults during the COVID-19 pandemic. JAMA Intern Med. 2022;182(janv):19–25.
pubmed: 34747982
doi: 10.1001/jamainternmed.2021.6454
Behnood SA, Shafran R, Bennett SD, Zhang AXD, O’Mahoney LL, Stephenson TJ, et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: a meta-analysis of controlled and uncontrolled studies. J Infect. 2022;84(févr):158–70.
pubmed: 34813820
doi: 10.1016/j.jinf.2021.11.011
Wisk LE, Gottlieb MA, Spatz ES, Yu H, Wang RC, Slovis BH, et al. Association of initial SARS-CoV-2 test positivity with patient-reported well-being 3 months after a symptomatic illness. JAMA Netw Open. 2022;5(déc):e2244486.
pubmed: 36454572
pmcid: 9716377
doi: 10.1001/jamanetworkopen.2022.44486
Zins M, Goldberg M, CONSTANCES team. The French cONSTANCES population-based cohort: design, inclusion and follow-up. Eur J Epidemiol. 2015;30(déc):1317–28.
pubmed: 26520638
pmcid: 4690834
doi: 10.1007/s10654-015-0096-4
Carrat F, de Lamballerie X, Rahib D, Blanché H, Lapidus N, Artaud F, et al. Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study. Int J Epidemiol. 2021;50(nov):1458–72.
pubmed: 34293141
doi: 10.1093/ije/dyab110
Morin AJS, Moullec G, Maïano C, Layet L, Just JL, Ninot G. Psychometric properties of the Center for Epidemiologic Studies Depression Scale (CES-D) in French clinical and nonclinical adults. Rev Epidemiol Sante Publique. 2011;59(oct):327–40.
pubmed: 21925817
doi: 10.1016/j.respe.2011.03.061
Goldberg DP, Gater R, Sartorius N, Ustun TB, Piccinelli M, Gureje O, et al. The validity of two versions of the GHQ in the WHO study of mental illness in general health care. Psychol Med. 1997;27(janv):191–7.
pubmed: 9122299
doi: 10.1017/S0033291796004242
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(sept):606–13.
pubmed: 11556941
pmcid: 1495268
doi: 10.1046/j.1525-1497.2001.016009606.x
Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374(juill):n1648.
pubmed: 34312178
doi: 10.1136/bmj.n1648
Nehme M, Braillard O, Alcoba G, Aebischer Perone S, Courvoisier D, Chappuis F, et al. COVID-19 symptoms: longitudinal evolution and persistence in outpatient settings. Ann Intern Med. 2021;174(mai):723–5.
pubmed: 33284676
doi: 10.7326/M20-5926
Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(juin):259–64.
pubmed: 33887749
doi: 10.1038/s41586-021-03553-9
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodological). 1995;57:289–300.
Storey JD. The positive false discovery rate: a Bayesian interpretation and the q-value. Ann Stat. 2003;31(déc):2013–35.
Gouraud C, Bottemanne H, Lahlou-Laforêt K, Blanchard A, Günther S, Batti SE, et al. Association between psychological distress, cognitive complaints, and neuropsychological status after a severe COVID-19 episode: a cross-sectional study. Front Psychiatry. 2021;12:725861.
pubmed: 34539470
pmcid: 8446522
doi: 10.3389/fpsyt.2021.725861
Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. N Engl J Med. 1999;341(oct):1329–35.
pubmed: 10536124
doi: 10.1056/NEJM199910283411801
Kohli P, Soler ZM, Nguyen SA, Muus JS, Schlosser RJ. The association between olfaction and depression: a systematic review. Chem Senses. 2016;41(juill):479–86.
pubmed: 27170667
pmcid: 4918728
doi: 10.1093/chemse/bjw061
Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand. 2017;135(mai):373–87.
pubmed: 28122130
doi: 10.1111/acps.12698
Koch C, Wilhelm M, Salzmann S, Rief W, Euteneuer F. A meta-analysis of heart rate variability in major depression. Psychol Med. 2019;49(sept):1948–57.
pubmed: 31239003
doi: 10.1017/S0033291719001351
Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. 2022;28(mai):911–23.
pubmed: 35585196
doi: 10.1038/s41591-022-01810-6
de Berker AO, Rutledge RB, Mathys C, Marshall L, Cross GF, Dolan RJ, et al. Computations of uncertainty mediate acute stress responses in humans. Nat Commun. 2016;7(mars):10996.
pubmed: 27020312
pmcid: 4820542
doi: 10.1038/ncomms10996
Anderson EC, Carleton RN, Diefenbach M, Han PKJ. The relationship between uncertainty and affect. Front Psychol. 2019;10:2504.
pubmed: 31781003
pmcid: 6861361
doi: 10.3389/fpsyg.2019.02504
Henningsen P, Gündel H, Kop WJ, Löwe B, Martin A, Rief W, et al. Persistent physical symptoms as perceptual dysregulation: a neuropsychobehavioral model and its clinical implications. Psychosom Med. 2018;80:422–31.
pubmed: 29621046
doi: 10.1097/PSY.0000000000000588
Engelmann P, Löwe B, Brehm TT, Weigel A, Ullrich F, Addo MM, et al. Risk factors for worsening of somatic symptom burden in a prospective cohort during the COVID-19 pandemic. Front Psychol. 2022;13:1022203.
pubmed: 36337508
pmcid: 9631939
doi: 10.3389/fpsyg.2022.1022203
Rozenkrantz L, Kube T, Bernstein MH, Gabrieli JDE. How beliefs about coronavirus disease (COVID) influence COVID-like symptoms? - A longitudinal study. Health Psychol. 2022;41(août):519–26.
pubmed: 35849379
doi: 10.1037/hea0001219
Sibelli A, Chalder T, Everitt H, Workman P, Windgassen S, Moss-Morris R. A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onset. Psychol Med. 2016;46(nov):3065–80.
pubmed: 27605134
doi: 10.1017/S0033291716001987
Creed F. A review of the incidence and risk factors for fibromyalgia and chronic widespread pain in population-based studies. Pain. 2020;161(juin):1169–76.
pubmed: 32040078
doi: 10.1097/j.pain.0000000000001819
Pollatos O, Traut-Mattausch E, Schandry R. Differential effects of anxiety and depression on interoceptive accuracy. Depress Anxiety. 2009;26:167–73.
pubmed: 19152366
doi: 10.1002/da.20504
Sidky H, Sahner DK, Girvin AT, Hotaling N, Michael SG, Gersing K. Assessing the Effect of Selective Serotonin Reuptake Inhibitors in the Prevention of Post-Acute Sequelae of COVID-19. medRxiv [Preprint]. 2023:2022.11.09.22282142. https://doi.org/10.1101/2022.11.09.22282142 .